TY - JOUR
T1 - Does acupuncture therapy affect peripheral inflammatory cytokines of major depressive disorder? A protocol for the systematic review and meta-analysis
AU - Zhao, Ya Nan
AU - Zhang, Shuai
AU - Chen, Yu
AU - Wang, Yu
AU - Chen, Hao
AU - Duan, Yu Ting
AU - Li, Shao Yuan
AU - Zhang, Zi Xuan
AU - Wang, Yi Fei
AU - Xin, Chen
AU - Li, Liang
AU - Rong, Pei Jing
N1 - This study was supported by the National Key R&D Program of China (No. 2018YFC1705800), the Acupuncture and Chronobiology Key Laboratory of Sichuan Province (No. 2021004), and the Fundamental Research Funds for the Central public welfare research institutes (ZZ15-YQ-048).
Publisher Copyright:
© 2022 Zhao, Zhang, Chen, Wang, Chen, Duan, Li, Zhang, Wang, Xin, Li and Rong.
PY - 2022/11/10
Y1 - 2022/11/10
N2 - Background: Acupuncture is widely used as adjuvant therapy for major depressive disorder (MDD). There is robust evidence that inflammation is closely associated with MDD. To date, only a few numbers of studies have investigated the potential relationship between acupuncture and the change of inflammatory biomarkers in patients with MDD. Additionally, the results are inconsistent among studies. The current study aims to provide a comprehensive, systematic review of the association between acupuncture and changes in peripheral inflammation of patients with MDD, and clarify the alterations of inflammatory cytokines before and after acupuncture treatment by meta-analysis. Methods and analysis: This study will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible randomized controlled trials (RCTs) reporting acupuncture, with inflammatory cytokines as the outcome measured before and after intervention in patients with MDD, were searched in electronic databases, such as PubMed, Embase, Cochrane, SINOMED, Wanfang, China national knowledge infrastructure (CNKI), and Chongqing VIP (CQVIP). Primary outcomes of interest will be validated to measure the levels of inflammatory cytokines before and after acupuncture treatment in patients with MDD. Discussion: Acupuncture can drive anti-inflammatory effects, as well as symptom changes in MDD, which may represent a viable, multi-faceted treatment approach in MDD. Systematic review registration: [PROSPERO], identifier [CRD42021289207 on 04 December 2021].
AB - Background: Acupuncture is widely used as adjuvant therapy for major depressive disorder (MDD). There is robust evidence that inflammation is closely associated with MDD. To date, only a few numbers of studies have investigated the potential relationship between acupuncture and the change of inflammatory biomarkers in patients with MDD. Additionally, the results are inconsistent among studies. The current study aims to provide a comprehensive, systematic review of the association between acupuncture and changes in peripheral inflammation of patients with MDD, and clarify the alterations of inflammatory cytokines before and after acupuncture treatment by meta-analysis. Methods and analysis: This study will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible randomized controlled trials (RCTs) reporting acupuncture, with inflammatory cytokines as the outcome measured before and after intervention in patients with MDD, were searched in electronic databases, such as PubMed, Embase, Cochrane, SINOMED, Wanfang, China national knowledge infrastructure (CNKI), and Chongqing VIP (CQVIP). Primary outcomes of interest will be validated to measure the levels of inflammatory cytokines before and after acupuncture treatment in patients with MDD. Discussion: Acupuncture can drive anti-inflammatory effects, as well as symptom changes in MDD, which may represent a viable, multi-faceted treatment approach in MDD. Systematic review registration: [PROSPERO], identifier [CRD42021289207 on 04 December 2021].
KW - acupuncture
KW - anti-inflammatory
KW - major depressive disorder
KW - peripheral inflammatory cytokines
KW - selective serotonergic reuptake inhibitors (SSRI)
UR - http://www.scopus.com/inward/record.url?scp=85142645868&partnerID=8YFLogxK
U2 - 10.3389/fneur.2022.967965
DO - 10.3389/fneur.2022.967965
M3 - Review article
AN - SCOPUS:85142645868
SN - 1664-2295
VL - 13
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 967965
ER -
